Emmaus Life Sciences to Participate in the Q4 Virtual Investor Summit

Torrance, California--(Newsfile Corp. - November 8, 2021) - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, will present a company overview at the Q4 Virtual Investor Summit on November 16, 2021 at 2:00 p.m. ET.

Dr. Niihara will highlight Endari®, the company's FDA approved prescription grade L-glutamine oral powder indicated to reduce the acute complications of sickle cell disease. Management will also host one-one-one meetings with qualified investors.

A live webcast of the presentation will be available on the "News and Events" section of the Emmaus website at: https://ir.emmausmedical.com/news-events. An archived replay will be available for a period of 90 days after the conference.

The conference is complimentary to qualified investors. Please register at Complimentary Investor Registration

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder) indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. For more information, please visit www.emmausmedical.com.

Forward-looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the anticipated benefits of the new online services. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including the risk that the expanded support services may not translate into increased Endari® sales and uncertainties and risk factors disclosed in the company's 2020 Annual Report on Form 10-K/A filed with the SEC on August 10, 2021, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

Company Contact:
Emmaus Life Sciences, Inc.
Willis Lee
Chief Operating Officer
(310) 214-0065 x1130
wlee@emmauslifesciences.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102039